New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access